Seminars in Oncology
Volume 33 , Pages 14-23 , December 2006

Molecular Biology of Colorectal Cancer: New Targets

  • Krit Kitisin

      Affiliations

    • Departments of Surgery and Medicine, Laboratory of Digestive Diseases, Georgetown University, Washington, DC
    • ,
  • Lopa Mishra

      Affiliations

    • Departments of Surgery and Medicine, Laboratory of Digestive Diseases, Georgetown University, Washington, DC
    • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
    • Veterans Affairs Medical Center, Washington, DC
    • Corresponding Author InformationAddress reprint requests to Lopa Mishra, MD, Georgetown University, Medical/Dental Building NW 210-213, 3900 Reservoir Road, NW, Washington, DC 20007, USA

References 

  1. Bluegrass Coalition for Colorectal Screening, KMA Cancer Committee. Colorectal cancer facts. J Ky Med Assoc. 2005;103:118
  2. Russo MW, Wei JT, Thiny MT, et al. Digestive and liver diseases statistics, 2004. Gastroenterology. 2004;126:1448–1453
  3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  4. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36
  5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  6. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170
  7. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649
  8. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science. 1998;280:1036–1037
  9. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13:63–69
  10. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138–141
  11. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001;29:25–33
  12. Lammi L, Arte S, Somer M, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet. 2004;74:1043–1050
  13. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 1994;54:5523–5526
  14. Khaleghpour K, Li Y, Banville D, et al. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis. 2004;25:241–248
  15. Shibata D, Peinado MA, Ionov Y, et al. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet. 1994;6:273–281
  16. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–932
  17. Taipale J, Beachy PA. The Hedgehog and Wnt signaling pathways in cancer. Nature. 2001;411:349–354
  18. Aaltonen LA. Hereditary intestinal cancer. Semin Cancer Biol. 2000;10:289–298
  19. Howe JR, Klimstra DS, Moccia RD, et al. Factors predictive of survival in ampullary carcinoma. Ann Surg. 1998;228:87–94
  20. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001;28:184–187
  21. Tang Y, Katuri V, Srinivasan R, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res. 2005;65:4228–4237
  22. Katuri V, Tang Y, Marshall B, et al. Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer. Oncogene. 2005;24:8012–8024
  23. Brittan M, Wright NA. The gastrointestinal stem cell. Cell Prolif. 2004;37:35–53
  24. Lin H. The stem-cell niche theory: lessons from flies. Nat Rev Genet. 2002;3:931–940
  25. Booth C, Potten CS. Gut instincts: Thoughts on intestinal epithelial stem cells. J Clin Invest. 2000;105:1493–1499
  26. Radtke F, Clevers H. Self-renewal and cancer of the gut: Two sides of a coin. Science. 2005;307:1904–1909
  27. Lickert H, Kispert A, Kutsch S, et al. Expression patterns of Wnt genes in mouse gut development. Mech Dev. 2001;105:181–184
  28. Holcombe RF, Marsh JL, Waterman ML, et al. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol. 2002;55:220–226
  29. Villanueva A, Garcia C, Paules AB, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene. 1998;17:1969–1978
  30. Xu X, Brodie SG, Yang X, et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene. 2000;19:1868–1874
  31. Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 1999;59:320–324
  32. Woodford-Richens KL, Rowan AJ, Gorman P, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci U S A. 2001;98:9719–9723
  33. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700
  34. Sporn MB. TGF-beta: 20 years and counting. Microbes Infect. 1999;1:1251–1253
  35. Zhou XP, Woodford-Richens K, Lehtonen R, et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet. 2001;69:704–711
  36. Kimchi A, Wang XF, Weinberg RA, et al. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science. 1988;240:196–199
  37. Chen RH, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science. 1993;260:1335–1338
  38. Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370:341–347
  39. Massague J, Cheifetz S, Laiho M, et al. Transforming growth factor-beta. Cancer Surv. 1992;12:81–103
  40. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature. 2003;425:577–584
  41. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998;394:909–913
  42. Tang Y, Katuri V, Dillner A, et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science. 2003;299:574–577
  43. Tsukazaki T, Chiang TA, Davison AF, et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998;95:779–791
  44. Dong C, Li Z, Alvarez R, et al. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell. 2000;5:27–34
  45. Mishra B, Tang Y, Katuri V, et al. Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-spectrin, in primary biliary cirrhosis. Liver Int. 2004;24:637–645
  46. Mishra L, Cai T, Yu P, et al. Elf3 encodes a novel 200-kD beta-spectrin: Role in liver development. Oncogene. 1999;18:353–364
  47. Tang Y, Katuri V, Iqbal S, et al. ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene. Oncogene. 2002;21:5255–5267
  48. Mishra L, Tully RE, Monga SP, et al. Praja1, a novel gene encoding a RING-H2 motif in mouse development. Oncogene. 1997;15:2361–2368
  49. Yu P, Chen Y, Tagle DA, et al. PJA1, encoding a RING-H2 finger ubiquitin ligase, is a novel human X chromosome gene abundantly expressed in brain. Genomics. 2002;79:869–874
  50. Mishra L, Katuri V, Evans S. The role of PRAJA and ELF in TGF-beta signaling and gastric cancer. Cancer Biol Ther. 2005;4:694–699
  51. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336–1338
  52. Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995;55:5545–5547
  53. Bellone G, Carbone A, Tibaudi D, et al. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer. 2001;37:224–233
  54. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167–4171
  55. Gajdusek CM, Luo Z, Mayberg MR. Basic fibroblast growth factor and transforming growth factor beta-1: Synergistic mediators of angiogenesis in vitro. J Cell Physiol. 1993;157:133–144
  56. Choi ME, Ballermann BJ. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J Biol Chem. 1995;70:21144–211450
  57. Dickson RB, Kasid A, Huff KK, et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A. 1987;84:837–841
  58. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol. 1996;179:297–302
  59. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137–161
  60. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect. 1999;1:1275–1282
  61. Miettinen PJ, Ebner R, Lopez AR, et al. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J Cell Biol. 1994;127:2021–2036
  62. Santibanez JF, Frontelo P, Iglesias M, et al. Urokinase expression and binding activity associated with the transforming growth factor beta1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. J Cell Biochem. 1999;74:61–73
  63. Nucci MR, Robinson CR, Longo P, et al. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum Pathol. 1997;28:1396–1407
  64. Matsumoto A, Hashimoto K, Yoshioka T, et al. Occlusion and subsequent re-canalization in early duodenal development of human embryos: Integrated organogenesis and histogenesis through a possible epithelial-mesenchymal interaction. Anat Embryol (Berl). 2002;205:53–65
  65. Bulow S. Familial polyposis coli. Dan Med Bull. 1987;34:1–15
  66. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology. 1991;100:1658–1664
  67. Bulow S, Alm T, Fausa O, et al. DAF Project Group Duodenal adenomatosis in familial adenomatous polyposis. Int J Colorectal Dis. 1995;10:43–46
  68. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet. 1998;62:1290–1301
  69. Wallis YL, Morton DG, McKeown CM, et al. Molecular analysis of the APC gene in 205 families: Extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet. 1999;36:14–20
  70. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 1997;17:79–83
  71. Cadigan KM, Nusse R. Wnt signaling: A common theme in animal development. Genes Dev. 1997;11:3286–3305
  72. Miller JR. The Wnts. Genome Biol. 2002;3:3001
  73. Moon RT, Shah K. Developmental biology: Signalling polarity. Nature. 2002;417:239–240
  74. Kishida M, Koyama S, Kishida S, et al. Axin prevents Wnt-3a-induced accumulation of beta-catenin. Oncogene. 1999;18:979–985
  75. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1–24
  76. Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 1998;92:645–656
  77. Cullingworth J, Hooper ML, Harrison DJ, et al. Carcinogen-induced pancreatic lesions in the mouse: Effect of Smad4 and Apc genotypes. Oncogene. 2002;21:4696–4701
  78. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027–1038
  79. Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993;260:810–812
  80. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst. 1995;87:1114–1125
  81. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–1027
  82. Umar A, Terdiman JP, Syngal S, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268
  83. Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet. 2000;9:283–287
  84. Shin KH, Park YJ, Park JG. PTEN gene mutations in colorectal cancers displaying microsatellite instability. Cancer Lett. 2001;174:189–194
  85. Jarvinen H, Franssila KO. Familial juvenile polyposis coli; increased risk of colorectal cancer. Gut. 1984;25:792–800
  86. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169–178
  87. Haramis AP, Begthel H, van den Born M, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science. 2004;303:1684–1686
  88. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: The problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994;81:7–19
  89. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer. 1998;34:2176–2183
  90. Petrelli N, Douglass HO, Herrera L, et al. Gastrointestinal Tumor Study Group The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol. 1989;7:1419–1426
  91. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5:1559–1565
  92. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147
  93. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2000;355:1041–1047
  94. Saltz LB, Cox JV, Blanke C, et al. Irinotecan Study Group Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–914
  95. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30
  96. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol. 2005;23:4553–4560
  97. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454–2460
  98. Salomon DS, Normanno N, Ciardiello F, et al. The role of amphiregulin in breast cancer. Breast Cancer Res Treat. 1995;33:103–114
  99. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  100. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6:2803–2807
  101. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78:1379–1384
  102. Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut. 2005;54:1194–1202

 This work was supported by the Sally Funderburg award (to L.M.) and National Institutes of Health grant nos. RO1 DK56111 (to L.M.), RO1 CA106614 (to L.M.), and VA Merit Award (to L.M.).

PII: S0093-7754(06)00380-0

doi: 10.1053/j.seminoncol.2006.10.003

Seminars in Oncology
Volume 33 , Pages 14-23 , December 2006

Article Tools

* Image Usage & Resolution